144 related articles for article (PubMed ID: 32086868)
1. Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study.
Scalambrino E; Padovan L; Chantarangkul V; Clerici M; Artoni A; Peyvandi F; Tripodi A
Int J Lab Hematol; 2020 Jun; 42(3):e128-e131. PubMed ID: 32086868
[No Abstract] [Full Text] [Related]
2. Monitoring of the anticoagulants argatroban and lepirudin: a comparison of laboratory methods.
Ivandic B; Zorn M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):549-55. PubMed ID: 20834029
[TBL] [Abstract][Full Text] [Related]
3. Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban.
Tripodi A; Chantarangkul V; Padovan L; Clerici M; Scalambrino E; Peyvandi F
J Thromb Thrombolysis; 2020 Apr; 49(3):413-419. PubMed ID: 31728842
[TBL] [Abstract][Full Text] [Related]
4. The effects of argatroban on thrombin generation and hemostatic activation in vitro.
Tanaka KA; Szlam F; Katori N; Sato N; Vega JD; Levy JH
Anesth Analg; 2004 Nov; 99(5):1283-1289. PubMed ID: 15502018
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals.
Berry CN; Lunven C; Lecoffre C; Lainée P; O'Connor SE; André F; Roger B; Garrigou-Gadenne D; Rouchouse A; Roome NO; Vivan N
Thromb Haemost; 2000 Aug; 84(2):278-85. PubMed ID: 10959701
[TBL] [Abstract][Full Text] [Related]
6. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study.
Rössig L; Genth-Zotz S; Rau M; Heyndrickx GR; Schneider T; Gulba DC; Desaga M; Buerke M; Harder S; Zeiher AM;
Int J Cardiol; 2011 Apr; 148(2):214-9. PubMed ID: 20226548
[TBL] [Abstract][Full Text] [Related]
7. Use of argatroban during multi-organ procurement: pharmacokinetics and sequelae in recipient of transplanted liver.
Schwartz JJ; Hatch JM; Book Z; Lonardo N; Hutson WR; Sorensen JB
Clin Transplant; 2009; 23(5):705-9. PubMed ID: 19637991
[TBL] [Abstract][Full Text] [Related]
8. Argatroban.
Kathiresan S; Shiomura J; Jang IK
J Thromb Thrombolysis; 2002 Feb; 13(1):41-7. PubMed ID: 11994559
[TBL] [Abstract][Full Text] [Related]
9. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
Van Cott EM; Roberts AJ; Dager WE
Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
[TBL] [Abstract][Full Text] [Related]
10. Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage.
Kitaoka T; Hua Y; Xi G; Hoff JT; Keep RF
Stroke; 2002 Dec; 33(12):3012-8. PubMed ID: 12468805
[TBL] [Abstract][Full Text] [Related]
11. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
Akimoto K; Klinkhardt U; Zeiher A; Niethammer M; Harder S
J Clin Pharmacol; 2011 Jun; 51(6):805-18. PubMed ID: 20663996
[TBL] [Abstract][Full Text] [Related]
13. Management of argatroban surrounding a lumbar puncture: a case report.
Faust AC; Oliphant CS
Am J Hematol; 2011 Aug; 86(8):720. PubMed ID: 21761442
[No Abstract] [Full Text] [Related]
14. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban.
Gray E; Harenberg J;
J Thromb Haemost; 2005 Sep; 3(9):2096-7. PubMed ID: 16102117
[No Abstract] [Full Text] [Related]
15. Thrombin inhibition in the acute phase of ischaemic stroke using argatroban.
Kario K; Kodama K; Koide M; Matsuo T
Blood Coagul Fibrinolysis; 1995 Jul; 6(5):423-7. PubMed ID: 8589208
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.
Beyer JT; Lind SE; Fisher S; Trujillo TC; Wempe MF; Kiser TH
J Thromb Thrombolysis; 2020 Feb; 49(2):259-267. PubMed ID: 31559512
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
18. Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time.
Keyl C; Lehane C; Zimmer E; Trenk D
Thromb Haemost; 2016 Nov; 116(6):1180-1181. PubMed ID: 27628460
[No Abstract] [Full Text] [Related]
19. Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Seidel H; Kolde HJ
Clin Appl Thromb Hemost; 2018 Mar; 24(2):287-294. PubMed ID: 28320219
[TBL] [Abstract][Full Text] [Related]
20. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia.
Keyl C; Zimmer E; Bek MJ; Wiessner M; Trenk D
Thromb Haemost; 2016 Jun; 115(6):1081-9. PubMed ID: 26792118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
